Join the Organ Transplant - Rejection Prophylaxis group to help and get support from people like you.
Organ Transplant - Rejection Prophylaxis News
Levothyroxine Infusion Does Not Increase Heart Transplants Versus Saline Infusion
THURSDAY, Nov. 30, 2023 – Intravenous levothyroxine infusion does not result in more hearts being transplanted than saline infusion among hemodynamically unstable brain-dead potential heart donors,...
Second Person to Receive Pig Heart Dies Six Weeks After Transplant
WEDNESDAY, Nov. 1, 2023 – The second person to ever receive a transplanted pig heart has died. Lawrence Faucette, 58, got the transplant just six weeks earlier at the University of Maryland Medical C...
Implant Can Warn Weeks Early That Transplanted Organ Will Be Rejected
FRIDAY, Sept. 8, 2023 – Receiving an organ transplant can be a nerve-wracking, if lifesaving, affair, said Dr. Joaquin Brieva, a kidney transplant recipient. “Within two days of my transplant, my k...
In Primate Study, Antibody Treatment Prevents Organ Rejection After Transplant
THURSDAY, Aug. 31, 2023 – A new study in non-human primates shows potential for using a manmade monoclonal antibody to help prevent organ rejection after a transplant. The antibody was successful in...
FDA Approves Expansion of CellCept (mycophenolate mofetil) Indication to Pediatric Heart Transplant and Pediatric Liver Transplant Populations
June 8, 2022 – FDA has expanded the use of CellCept (mycophenolate mofetil) to prophylaxis of organ rejection in pediatric recipients of allogenic heart and allogeneic liver transplants aged 3...
U.S. Food and Drug Administration Expands Indication for Prograf for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has...
Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection
NORTHBROOK, Ill., July 19, 2013 /PRNewswire/ – Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug...
FDA Approves Nulojix for Kidney Transplant Patients
SILVER SPRING, Md., June 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a...
Ask a question
To post your own question to this support group, sign in or create an account.